J.P. Morgan Notebook, Jan. 11: Pfizer/Allergan, Celgene, Gilead And More
This article was originally published in The Pink Sheet Daily
Executive Summary
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Sponsors Drive CARs To The Next Destination: Pivotal Trials
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.